hVIVO upgraded to Buy by Numis despite CEO resignation
In a note to clients, analysts for the broker said the biotech firm had indicated a more coherent strategy that reflected value despite recent weak share performance
Company
hVIVO PLC
LON:HVO
hVIVO plc (Ticker: HVO) is a full-service early phase Contract Research Organisation (CRO) and the global leader in human challenge trials. The Company delivers end-to-end clinical development services to a diverse and expanding client base, including seven of the world’s ten largest biopharma companies. hVIVO specialises in conducting human challenge trials across multiple infectious and respiratory indications, leveraging its state-of-the-art quarantine facility in London—the largest of its kind worldwide. The Company also offers comprehensive virology and immunology laboratory services under the hLAB brand. Through its German subsidiary, CRS , hVIVO operates a 120-bed capacity across Mannheim and Kiel, providing early-phase clinical trial services, including first-in-human and proof-of-concept studies. Its second subsidiary, Venn Life Sciences, offers Early Drug Development Consulting and Biometry services to the biopharma sector. The Group provides fully integrated drug development solutions from preclinical stages through Phase II trials, alongside patient recruitment via FluCamp . Additionally, its five clinical sites support outpatient Phase II and III trials, ensuring a seamless and efficient pathway from discovery to late-stage development.
190 stories · page 10 of 10
FTSE 100 closes in the black as Shire surges; tobacco stocks drift lower
Shire shares ended 5.89% up as the group received and rejected a takeover approach from Japan's Takeda Pharma
Investments and investor services
Unilever, Debenhams and Rentokil Initial in the spotlight as updates loom
Thursday looks a pretty busy day for investors with a number of important updates due.
Archive
High street issues to the fore as Debenhams, JD Sports, and Primark owner AB Foods provide updates
Week Ahead includes trading statements from Primark owner Associated British Foods, Debenhams, and JD Sports, plus Q1 numbers from Unilever, Reckitt Benckiser and Rentokil Initial
D4t4 jumps as two ‘biggest ever contracts’ boost revenues and profits
The medical diagnostics group is planning on closing its sites in India and Germany as it looks to get back to profitability from a smaller revenue base
Shire shares lifted by Japanese takeover talk
A look at some of the biggest risers and fallers in London on Thursday.
Xtract Resources shines after Aurioch settlement
Some of the biggest risers and fallers in London at 3.15pm: Xtract Resources, CyanConnode, Wishbone Gold, Victoria Oil & Gas, Thomas Cook, Baron Oil
hVIVO’s landmark asthma study underway
The firm has inoculated its first volunteer with human rhinovirus at its London-based clinical research unit
hVIVO gives strong backing to £20mln fundraiser
Put very simply the company’s scientists develop human models of disease that help drug companies and research groups find better treatments.